US Patent

US10881618 — Compositions for treatment of attention deficit hyperactivity disorder

Method of Use · Assigned to Ironshore Pharmaceuticals and Development Inc Cayman Island · Expires 2032-03-23 · 6y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a delayed and extended release formulation of methylphenidate for the treatment of attention deficit hyperactivity disorder.

USPTO Abstract

Therapeutic compositions deliver a therapeutic amount of methylphenidate in a delayed and extended release formulation. The dosage form exhibits a lag time prior to release of from 6 to 8 hours or longer, followed by a sustained release period.

Drugs covered by this patent

methylphenidate-hydrochloride (METHYLPHENIDATE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2357`	—	methylphenidate-hydrochloride
`U-2357`	—	methylphenidate-hydrochloride
`U-2357`	—	methylphenidate-hydrochloride
`U-2357`	—	methylphenidate-hydrochloride
`U-2357`	—	methylphenidate-hydrochloride

Patent Metadata

Patent number: US10881618
Jurisdiction: US
Classification: Method of Use
Expires: 2032-03-23
Drug substance claim: No
Drug product claim: No
Assignee: Ironshore Pharmaceuticals and Development Inc Cayman Island
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.